Bioequivalence of Two Tablet Forms of MK0974 (0974-045)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the bioequivalence of two solid dose formulations of MK0974.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)

NCT01209741

Migraine

COMPLETED PHASE1

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

NCT00662818

Migraine Disorders Heart Disease Cerebrovascular Accident +3 more

COMPLETED PHASE3

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

NCT00432237

Migraine

COMPLETED PHASE3

A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

NCT00246337

Migraine

COMPLETED PHASE2

MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

NCT00797667

Migraine

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

MK0974 Ethanolate

Group Type ACTIVE_COMPARATOR

MK0974 Ethanolate formulation

Intervention Type DRUG

Single dose MK0974 280 mg tablet in one of two treatment periods

2

MK0974 Hydrate

Group Type ACTIVE_COMPARATOR

Comparator: MK0974 Hydrate formulation

Intervention Type DRUG

Single dose MK0974 280 mg tablet in one of two treatment periods

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0974 Ethanolate formulation

Single dose MK0974 280 mg tablet in one of two treatment periods

Intervention Type DRUG

Comparator: MK0974 Hydrate formulation

Single dose MK0974 280 mg tablet in one of two treatment periods

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is in good health
* Subject is a non-smoker
* Subject is willing to comply with the study restrictions

Exclusion Criteria

* Subject has a history of stroke, chronic seizures, or major neurological disorder
* Subject has a history of cancer
* Subject is a nursing mother
* Subject has or has a history of any disease or condition that might make participation in the study unsafe or that might confound the results of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes